<DOC>
	<DOCNO>NCT03081676</DOCNO>
	<brief_summary>The prevalent monogenetic diabetic subtype name maturity onset diabetes young type ( MODY3 ) hepatocyte nuclear factor 1α ( HNF1A ) -diabetes . The aim study evaluate effect supra-physiological level GIP GLP-1 , respectively , insulin glucagon secretion fast plasma glucose ( FPG ) `` post-prandial '' PG level ( 1.5 × FPG ) patient HNF1A-diabetes match healthy control treat without low dose glimepiride ( sulphonylurea ) . In addition , evaluate maximal insulin glucagon secretory capacity group .</brief_summary>
	<brief_title>The Effect GIP GLP-1 Insulin Glucagon Secretion Patients With HNF1A-diabetes Treated With Without Sulphonylurea</brief_title>
	<detailed_description>A total 6 experimental day perform . The following outline experimental day : Participants meet 10-hour fast . A tablet glimepiride 1.0 mg placebo administer 90 minute initiation experiment ( -90 minute ) The mean FPG calculate blood sample -105 , -100 -90 minute . Two intravenous cannula insert cubital vein arm . One intravenous cannula use infusion glucose , arginine GIP use collect venous blood . The forearm blood sample draw place heating pad ( 50°C ) throughout experiment arterialisation venous blood . At time 0 minute , glucose clamp establish FPG level 60 minute hereafter post-prandial clamp period 1.5 × FPG another 60 minute . At time 120 minute , bolus 5g L-arginine ( give 50 % arginine HCl ) infuse 30 second . The post-prandial clamp maintain another 10 minute time 130 minute prevent reactive hypoglycaemia . Throughout experiment ( 0-130 minute ) continuous infusion either GIP ( 1.5 pmol/kg/min ) , GLP-1 ( 0.5 pmol/kg/min ) placebo ( saline ) administer . During experiment PG keep stable continuous 20 % -glucose infusion . The rate infusion regulate accord PG determine bed-site measurement every 5 minute . After 60 minute , post-prandial clamp establish bolus infusion one minute use 50 % -glucose target 1.5 × FPG ( amount glucose administer calculated follow : ( 1.5 × FPG - FPG ) × 35 mg glucose × weight kilogram ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Participants Ten patient HNF1Adiabetes ten match healthy control recruit . Different inclusion exclusion criterion apply two group : Inclusion criterion HNF1Apatients Patients HNF1Adiabetes verify genetic testing Patients treat diet sulphonylurea monotherapy Normal haemoglobin ( male 8.310.5 mmol/l , females 7.39.5 mmol/l ) Informed consent Exclusion criterion HNF1Apatients Nephropathy ( estimate glomerular filtration rate ( eGFR ) &lt; 60 ml/min/1.73m2 and/or albuminuria ) Liver disease ( serum alanine aminotransferase ( ALT ) and/or serum aspartate aminotransferase ( AST ) 2 × normal value ) Pregnancy breastfeed Inclusion criterion healthy control FPG ≤6 mmol/l glycated haemoglobin ( HbA1c ) ≤43 mmol/mol Normal haemoglobin define Age ≥18 year Informed consent Exclusion criterion healthy control No family history type 1 type 2 diabetes Nephropathy ( define ) Liver disease ( define ) Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Maturity-Onset Diabetes Young , Type 3</keyword>
	<keyword>Glucose-dependent insulinotropic peptide</keyword>
	<keyword>Glucagon-like-peptide 1</keyword>
	<keyword>Dipeptidyl peptidase 4</keyword>
	<keyword>Glimepiride</keyword>
	<keyword>Sulphonylurea</keyword>
	<keyword>Glucose clamp</keyword>
	<keyword>Hepatocyte nuclear factor 1 alpha</keyword>
</DOC>